Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

A muscleblind knockout model for myotonic dystrophy.

Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers AM, Hauswirth WW, Swanson MS.

Science. 2003 Dec 12;302(5652):1978-80.

2.

Pathogenic mechanisms of myotonic dystrophy.

Lee JE, Cooper TA.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1281-6. doi: 10.1042/BST0371281. Review.

3.

The Muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing.

Pascual M, Vicente M, Monferrer L, Artero R.

Differentiation. 2006 Mar;74(2-3):65-80. Review.

PMID:
16533306
4.

Myotonic syndromes.

Mankodi A, Thornton CA.

Curr Opin Neurol. 2002 Oct;15(5):545-52. Review.

PMID:
12351998
5.

Gain of RNA function in pathological cases: Focus on myotonic dystrophy.

Klein AF, Gasnier E, Furling D.

Biochimie. 2011 Nov;93(11):2006-12. doi: 10.1016/j.biochi.2011.06.028. Epub 2011 Jul 13. Review.

PMID:
21763392
6.

Myotonic dystrophy: RNA-mediated muscle disease.

Wheeler TM, Thornton CA.

Curr Opin Neurol. 2007 Oct;20(5):572-6. Review.

PMID:
17885447
7.

[Myotonic dystrophy: therapeutic approaches to RNA toxicity].

Nakamori M, Takahashi MP.

Brain Nerve. 2011 Nov;63(11):1161-8. Review. Japanese.

PMID:
22068468
8.

Myotonic dystrophy mouse models: towards rational therapy development.

Gomes-Pereira M, Cooper TA, Gourdon G.

Trends Mol Med. 2011 Sep;17(9):506-17. doi: 10.1016/j.molmed.2011.05.004. Epub 2011 Jul 2. Review.

9.

MBNL proteins and their target RNAs, interaction and splicing regulation.

Konieczny P, Stepniak-Konieczna E, Sobczak K.

Nucleic Acids Res. 2014;42(17):10873-87. doi: 10.1093/nar/gku767. Epub 2014 Sep 2. Review.

10.

[Myotonia and cardiac conduction defects in myotonic dystrophy and defect in ion channels].

Kubota T, Nakamori M, Takahashi MP.

Rinsho Byori. 2014 Mar;62(3):246-54. Review. Japanese.

PMID:
24800500
11.

RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity.

Echeverria GV, Cooper TA.

Brain Res. 2012 Jun 26;1462:100-11. doi: 10.1016/j.brainres.2012.02.030. Epub 2012 Feb 22. Review.

12.

[Myotonic dystrophy].

Ishiura S, Oana K, Koebis M.

Rinsho Shinkeigaku. 2013;53(11):1109-11. Review. Japanese.

PMID:
24291894
13.

RNA-dominant diseases.

Osborne RJ, Thornton CA.

Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R162-9. Review.

PMID:
16987879
14.

Regulation of splicing by MBNL and CELF family of RNA-binding protein.

Ishiura S, Kino Y, Nezu Y, Onishi H, Ohno E, Sasagawa N.

Acta Myol. 2005 Oct;24(2):74-7. Review.

PMID:
16550919
15.

Myotonic dystrophy: therapeutic strategies for the future.

Wheeler TM.

Neurotherapeutics. 2008 Oct;5(4):592-600. doi: 10.1016/j.nurt.2008.08.001. Review.

16.

[Myotonic Dystrophy: Advances in Translational Research].

Nakamori M, Takahashi MP.

Brain Nerve. 2017 Jan;69(1):61-69. doi: 10.11477/mf.1416200637. Review. Japanese.

PMID:
28126979
17.

Roles for RNA-binding proteins in development and disease.

Brinegar AE, Cooper TA.

Brain Res. 2016 Sep 15;1647:1-8. doi: 10.1016/j.brainres.2016.02.050. Epub 2016 Mar 10. Review.

18.

Myotonic dystrophy: discussion of molecular basis.

Timchenko LT, Tapscott SJ, Cooper TA, Monckton DG.

Adv Exp Med Biol. 2002;516:27-45. Review. No abstract available.

PMID:
12611434
19.

Alternative splicing and muscular dystrophy.

Pistoni M, Ghigna C, Gabellini D.

RNA Biol. 2010 Jul-Aug;7(4):441-52. Epub 2010 Jul 1. Review.

20.

Congenital myotonic dystrophy-an RNA-mediated disease across a developmental continuum.

Jagannathan S, Bradley RK.

Genes Dev. 2017 Jun 1;31(11):1067-1068. doi: 10.1101/gad.302893.117. Review.

PMID:
28717044

Supplemental Content

Support Center